Hangzhou Baicreat Pharma-Tech Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer.

Onco3r Therapeutics BV has synthesized cellular tumor antigen p53 (TP53) Y220C mutant stabilizers reported to be useful for the treatment of cancer.

Genome Therapeutics Ltd. has disclosed compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Apollo AP45 Ltd. has described eukaryotic translation initiation factor 2-α kinase 3 (PERK) inhibitors reported to be useful for the treatment of cancer.

Inventisbio Co. Ltd. and Inventisbio LLC have divulged kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Nanjing Minova Pharmaceutical Co. Ltd. and Precision Brain Science Biotechnology (Suzhou) Co. Ltd. have identified salts of deuterated dextromethorphan reported to be useful for the treatment of cough, pain, epilepsy, cancer, rheumatoid arthritis, dermatitis, cardiovascular disorders and glaucoma.

Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have synthesized aza-tricyclic derivatives acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Shenzhen Targetrx Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a Bcr-Abl (Bcr-Abl1) kinase and its mutant targeting moiety through a linker reported to be useful for the treatment of cancer and immunological disorders.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described compounds acting as gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonists reported to be useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD, NAFLD), diabetes and obesity.

Chengdu Sibeibo Pharmaceutical Technology Co. Ltd. has divulged deuterated derivatives of taladegib acting as Hedgehog signaling inhibitors and protein smoothened (SMO) antagonists reported to be useful for the treatment of cancer and idiopathic pulmonary fibrosis.